Syros Pharmaceuticals, a Cambridge, Mass.-based cancer drug developer, relied on Ten Bridge Communications and Stern IR for support through its July 6 IPO.
Syros raised $57.5M with the Nasdaq listing, short of projections. The funds will be used to fund its drug trials focused on controlling genes that cause cancer.
Ten Bridge partner Naoi Aoki leads the PR account at her firm, which was founded by Feinstein Kean Healthcare alums Dan Quinn and Ann Stanesa.
Stern senior associate Jesse Baumgartner reps Syros at the IR firm.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
Haggie Partners is working the $7B takeover of the specialty insurer Convex by Canada’s Onex private equity fund and American International Group.
WPP reported Q3 revenues less pass-through costs tumbled 5.9 percent to $3.3B, a performance new CEO Cindy Rose called “unacceptable.”
